Maximum quantity allowed is 999
请选择数量
CAS RN: 755037-03-7 | 产品编码: R0142
Regorafenib
×
![]()
×
| 产品编码 | R0142 |
纯度/分析方法 
|
>98.0%(HPLC) |
| 分子式/分子量 | C__2__1H__1__5ClF__4N__4O__3 = 482.82 |
| 外观与形状（20°C） | 固体 |
| 储存温度
|
冷冻 (<0°C) |
| 应避免的情况 | 加热 |
| 包装和容器
|
100MG-Glass Bottle with Plastic Insert （查看图片）, 25MG-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 755037-03-7 |
| Reaxys-RN | 14359949 |
| PubChem物质ID | 354334233 |
| MDL编号 | MFCD16038047 |
技术规格
| Appearance | White to Light yellow to Light orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Elemental analysis(Nitrogen) | 11.00 to 12.20 % |
物性（参考值）
| 熔点 | 208 °C |
GHS
| 象形图 |
|
| 信号词 | Warning |
| 危险性说明 | H302 : Harmful if swallowed. H361 : Suspected of damaging fertility or the unborn child. H373 : May cause damage to organs through prolonged or repeated exposure. |
| 防范说明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
相关法规
运输信息
| HS编码* | 2933.39-000 |
应用
Regorafenib: A Multikinase Inhibitor of Tumour Angiogenesis, Oncogenesis and the Tumour Microenvironment
Regorafenib (BAY 73-4506) is a potent diphenylurea multikinase inhibitor of tumour angiogenesis (VEGFR1，VEGFR2，VEGFR3，TIE2), oncogenesis (KIT, RET, RAF-1, BRAF, BRAFV600E), and the tumour microenvironment (PDGFR-β, FGFR). Regorafenib has promising antineoplastic activity in various tumor types. Regorafenib is mainly metabolized by CYP3A4, and the major human metabolites M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl) are reported to exhibited similar efficacies compared to regorafenib in in vitro and in vivo models. For your reference, [A2979] is a key synthetic intermediate of regorafenib. (The product is for research purpose only.)
References
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- Regorafenib for cancer (a review)
- Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
- A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry
- Determination of regorafenib (BAY 73-4506) and its major human metabolites BAY 75-7495 (M-2) and BAY 81-8752 (M-5) in human plasma by stable-isotope dilution liquid chromatography-tandem mass spectrometry
参考文献
文档
技术文章
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。